View : 350 Download: 0
Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease
- Title
- Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease
- Authors
- Cho, In-Jeong; Kang, Seok-Min
- Ewha Authors
- 조인정
- SCOPUS Author ID
- 조인정
- Issue Date
- 2021
- Journal Title
- KIDNEY RESEARCH AND CLINICAL PRACTICE
- ISSN
- 2211-9132
2211-9140
- Citation
- KIDNEY RESEARCH AND CLINICAL PRACTICE vol. 40, no. 4, pp. 555 - 565
- Keywords
- Chronic kidney disease; Heart failure; Neprilysin; Renin-angiotensin-aldosterone system
- Publisher
- KOREAN SOC NEPHROLOGY
- Indexed
- SCIE; SCOPUS; KCI
- Document Type
- Review
- Abstract
- Despite significant advances in the management of heart failure with reduced ejection fraction (HFrEF), there remains an enormous health problem with high morbidity and mortality over the last few decades. The neprilysin inhibitor enhances the activity of natriuretic peptides, producing vasodilation, natriuresis, and diuresis. Angiotensin receptor blockers inhibit the renin-angiotensin-aldosterone system. Sacubitril/valsartan, a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI), has been shown to improve cardiovascu-lar outcomes in HFrEF and delay the progression of chronic kidney disease (CKD) in patients with HFrEF. The PARADIGM-HF study showed a reduction in diuretic need in the ARNI group. While the use of diuretics is effective in volume control in patients with HFrEF, their use has the potential to adversely affect renal function. Therefore, ARNI therapy could benefit patients with heart failure and CKD by reducing cardiovascular morbidity and mortality and possibly retarding the progression of CKD, although more clinical evi-dence is required in patients with severe CKD and end-stage renal disease.
- DOI
- 10.23876/j.krcp.21.900
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML